Phluence
Agentic patient services platform for pharmaceutical manufacturers, automating the post prescription access journey that determines whether a prescribed therapy ever reaches the patient. Named agents handle distinct functions: a consent agent manages opt in for sharing patient health information across manufacturers, specialty pharmacies, and provider hubs; a marketing agent personalizes educational outreach from multi source data; and an enrollment agent accelerates virtual hub enrollment by automating document verification, form completion, and payer navigation around the clock. Ships modular pre configured solutions including automated annual reverification, digital enrollment, bridge to copay sweeps, and click to agent conversational interfaces. The company positions itself as an alternative to traditional labor intensive hub models, where enrollment and reverification are handled by large human teams. Formerly Lifelink Systems, founded 2015; Precision AQ made a strategic investment in 2025 and named an incoming chief executive.
Capability Axes
Named agents perform the work: consent capture, enrollment document verification and form completion, payer navigation, and reverification. The company positions the platform explicitly against labor intensive hub models, meaning the AI replaces human process capacity rather than assisting it.
The company has operating history, founded 2015 as Lifelink Systems, and received a strategic investment from Precision AQ in 2025 alongside a new incoming chief executive, which is meaningful industry validation. However no enrollment volumes, cycle time reductions, named manufacturer customers, or measured outcomes were retrieved, and the rebrand makes prior track record harder to trace.
Notable that consent is built as a distinct agent rather than a checkbox: it manages opt in for sharing patient health information across manufacturers, specialty pharmacies, and provider hubs, which is the multi party disclosure problem at the center of pharma patient services and a genuine compliance function. Held back from A because certifications, audit posture, and data handling terms were not retrieved.
No public pricing. Enterprise pharma agreements arranged through sales, typically scoped to patient volume and program complexity.
Precisely bounded to the post prescription access journey for pharmaceutical manufacturers: enrollment, benefits and payer navigation, copay support, and annual reverification. No clinical claims are made, which is correct for what this does.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise pharma agreements scoped to patient volume and program complexity | — | — | Vendor Published |
No public pricing. Enterprise pharmaceutical agreements arranged through sales, typically scoped to patient volume and program complexity. The relevant comparison for a manufacturer is against the fully loaded cost of a traditional labor intensive hub, which is the model the company positions against.